Clinical Trials Browser

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

535 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06538038 2026-03-27

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Recruiting

538 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05143970 2026-03-20

CHANCES

Phase 1 Recruiting

27 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07472478 2026-03-16

GIVEN

Phase 2 Not yet recruiting

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04798664 2026-02-25

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

Phase NA Completed

3,228 enrolled 41 charts

Thoracic

Lung Neoplasms, Tobacco Use Disorder, Smoking Cessation

NCT07398937 2026-02-10

ECTOP-1036

Phase 2 Recruiting

116 enrolled

Thoracic

Lung Neoplasms

NCT06018376 2026-02-06

LUDICAS

Completed

553 enrolled 6 charts

OtherThoracic

Lung Neoplasms, Sexual Dysfunction, Physiological

NCT04151940 2026-01-14

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

Phase NA Recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07258147 2025-12-02

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Lung Neoplasms

NCT07256002 2025-12-01

Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

Active not recruiting

10,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06784791 2025-08-29

NEOpredict-EGF

Phase 2 Recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07135882 2025-08-22

PRIME-Lung

Phase 3 Not yet recruiting

420 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07076836 2025-07-22

Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Phase NA Not yet recruiting

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06598527 2025-05-29

SACTION2401

Phase 3 Recruiting

360 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06003075 2025-04-30

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Phase 2 Terminated

1 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04364048 2024-12-20

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 10 charts

Thoracic

Lung Neoplasms

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

45 enrolled

Thoracic

Lung Neoplasms

NCT06613308 2024-09-25

Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC

Not yet recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06585644 2024-09-05

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Phase 2 Not yet recruiting

44 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

200 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06292052 2024-05-14